The kidney benefits of SGLT2 inhibitors and finerenone are well proven in DKD.The demonstrated slowing of eGFR decline and reduction in incident ESKD arealmost certainly indicative of an important pharmacoeconomic benefit. This evidence concerns the gene SLC5A2 and diabetic kidney disease.